Hepatitis B is under research on a new drug edp-721, which belongs to a new type of oral hepatitis B virus RNA destabilizer. Biopharmaceutical company Enanta Pharmaceuticals will present preclinical data on this new oral HBVRNA stabilizer edp-721 at the 2021 International Liver Congress ™ sponsored by the European Association (see chart below: preclinical data from Enanta announcing that edp-721 will be presented soon).
Hepatitis B is researching a new drug edp-721, RNA destabilizer, and preclinical data will be announced at the European Liver Conference
Enanta is a leader in the discovery and development of small molecule drugs that leverage its strong chemically driven approach and drug discovery capabilities in the treatment of viral infections and liver diseases. The company's main pharmaceutical research areas include respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH), and new drug development in these areas has produced clinical drug candidates.
The details of the preclinical data presentation of edp-721 are as follows: The study drug will announce the preclinical study data on June 23, 2021 at 8:00 CET. Title: Discovery and Characterization of a Novel Hepatitis B Virus RNA Destabilizer edp-721 (Poster 942), the preclinical data presenter for edp-721 is Dr. Michael Vaine from the United States (below: From enanta hepatitis B drug development pipeline, visible in the red box is edp-721 latest progress).
EDP-721 R&D process sorted out
In early 2021, clinical-stage biotechnology company Enanta Pharmaceuticals announced EDP-721 as an additional ingredient for functionally cured HBV, and EDP-721 is expected to launch Phase 1 clinical trials in mid-2021. Simply put, Enanta is currently in clinical development with two candidates for the new hepatitis B drugs edp-721 and edp-514. The company's latest discovery of this oral RNA destable agent, edp-721, is a novel type of RNA that reduces multiple HBV protein production.
Its preclinically disclosed data show that edp-721 has the pan-genomic potential to lower the production of hepatitis B surface antigens, and that edp-721 and another of the company's new hepatitis B drugs under research, edp-514 (core inhibitors), have synergistic activity. Preclinical animal model studies of EDP-721 have shown a powerful reducing effect on HBV transcripts, resulting in reduced production of multiple hepatitis B virus proteins, which contain a reducing effect on hepatitis B surface antigens and e antigens.
From the perspective of mechanism of action, edp-721 is expected to reduce the hepatitis B surface antigen derived from integrated and covalent closed cyclic DNA (CCCDNA) mainly by targeting the RNA of hepatitis B virus. The company's other new hepatitis B drug under research, edp-514, has progressed faster than edp-721, and it is expected that edp-514 will announce phase 1b data from clinical trials in the second quarter of 2021.
Xiaofan Health Conclusion: Clinical-stage biotechnology company enanta pharmaceuticals is currently having two candidates for new hepatitis B drugs in clinical development. EDP-514 (Phase 1b), which is a core inhibitor and named by the US FDA Fast Track, currently has two clinical trials of the study drug, and preliminary data for these two clinical trials is expected to be available in the second quarter of 2021; the latest edp-721, which is a novel, effective and selective oral HBVRNA destabilizer, is expected to announce its preclinical data at the International Liver Congress on June 23-26, 2021. edp-721 (preclinical, about to enter clinical phase 1) is expected to start phase 1 clinical trials in mid-2021 (Note: new drug development has the characteristics of high investment, high risk, long cycle, involving multidisciplinary collaboration, and it is uncertain whether the final research results can be approved for marketing).